R. Benjamin Free
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
R. Benjamin Free has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- David R. Sibley
NINDS/NIH
19 shared publications - Lei Shi
National Institutes of Health
9 shared publications Amy E. Moritz
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
6 shared publications- J. Robert Lane
Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, UK
6 shared publications - Kevin J. Frankowski
University of North Carolina at Chapel Hill
5 shared publications - Julia Drube
Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany
4 shared publications
Latest Publications
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaeh3401
Multiple allosteric sites allow for synergistic enhancement of GPCR signaling
Allosteric modulation of G protein–coupled receptors (GPCRs) offers promising therapeutic opportunities. Although multiple allosteric binding sites have been identified in GPCRs, whether and how these spatially distinct sites cooperate to regulate receptor activation remain poorly understood. Here, we elucidate the molecular mechanism of cooperative multisite allostery in the dopamine D1 receptor (D1R). We developed two novel D1R positive allosteric modulators (PAMs), UNC9815 and UNC10062, and used cryo–electron microscopy to structurally identify two previously uncharacterized D1R allosteric sites occupied by UNC9815/UNC10062 and another D1R PAM, BMS-A1. Both sites localize to the transmembrane helix (TM) 1 to 7 interface as vertically adjacent allosteric pockets organized in a spatially complementary manner. Our structures demonstrate the simultaneous binding of the chemically distinct PAMs (LY3154207, BMS-A1, and UNC9815/UNC10062) in three nonoverlapping pockets. Concurrent engagement of all three allosteric sites produces pronounced functional cooperativity, increasing dopamine potency by >1000-fold, thereby demonstrating that coordinated multisite modulation can achieve substantial pharmacological amplification beyond the limits imposed by single PAM administration. Molecular dynamics (MD) simulations revealed that multisite PAM engagement restricts intracellular loop 3 dynamics and stabilizes the TM7-NPxxY activation motif, effects not achieved by binding of LY3154207 alone, thereby biasing the receptor toward a more stabilized active conformation, and may also improve agonist potency by stabilizing extracellular loop 2. Together, these findings establish the structural framework for cooperative multisite allostery in a GPCR, revealing how distributed allosteric sites act in concert to amplify receptor activation and providing a conceptual foundation for developing innovative GPCR allosteric therapeutics.
- 1 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16691-16749
Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor
To identify novel D3 dopamine receptor (D3R)-selective antagonist scaffolds, we conducted a high-throughput screen of a small-molecule library using a β-arrestin recruitment assay. The lead hit compound, MLS6357, displayed unprecedented D3R selectivity as well as unusual positive allosteric modulator (PAM)-antagonist activity, which may confer unique therapeutic advantages to this scaffold. Iterative medicinal chemistry was used to synthesize and characterize 137 analogues, with several demonstrating both high D3R selectivity and improved D3R potency in β-arrestin recruitment and G protein activation assays. Two of the more promising analogues with 10-fold or greater improvements in potency, 6a and 10aa, were further characterized and found to recapitulate both the allosteric PAM-antagonism and global D3R selectivity of MLS6357. 6a and 10aa also demonstrated favorable pharmacokinetics in mice suggesting that these compounds may serve as both research tools and therapeutic leads for the treatment of neuropsychiatric disorders, including substance use disorder.
- 1 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (15) , 16691-16749
Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor
To identify novel D3 dopamine receptor (D3R)-selective antagonist scaffolds, we conducted a high-throughput screen of a small-molecule library using a β-arrestin recruitment assay. The lead hit compound, MLS6357, displayed unprecedented D3R selectivity as well as unusual positive allosteric modulator (PAM)-antagonist activity, which may confer unique therapeutic advantages to this scaffold. Iterative medicinal chemistry was used to synthesize and characterize 137 analogues, with several demonstrating both high D3R selectivity and improved D3R potency in β-arrestin recruitment and G protein activation assays. Two of the more promising analogues with 10-fold or greater improvements in potency, 6a and 10aa, were further characterized and found to recapitulate both the allosteric PAM-antagonism and global D3R selectivity of MLS6357. 6a and 10aa also demonstrated favorable pharmacokinetics in mice suggesting that these compounds may serve as both research tools and therapeutic leads for the treatment of neuropsychiatric disorders, including substance use disorder.
- Open Access
- 20 October 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1552
G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D2 Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation
The D2 dopamine receptor (D2R) signals through both G proteins and β-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. β-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, receptor phosphorylation is indispensable for β-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for β-arrestin recruitment to the D2R, and the role of GRKs in D2R–β-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine the extent to which β-arrestin recruitment to the D2R is GRK-dependent. Genetic elimination of all GRK expression decreased, but did not eliminate, agonist-stimulated β-arrestin recruitment to the D2R or its subsequent internalization. However, these processes were rescued upon the re-introduction of various GRK isoforms in the cells with GRK2/3 also enhancing dopamine potency. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, decreased β-arrestin recruitment and receptor internalization, highlighting the importance of this GRK subfamily for D2R–β-arrestin interactions. These results were recapitulated using a phosphorylation-deficient D2R mutant, emphasizing that GRKs can enhance β-arrestin recruitment and activation independently of receptor phosphorylation.
- 20 October 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (10) , 1552
Open AccessG Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D2 Dopamine Receptor through Mechanisms That Are Independent of Receptor Phosphorylation
The D2 dopamine receptor (D2R) signals through both G proteins and β-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. β-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, receptor phosphorylation is indispensable for β-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for β-arrestin recruitment to the D2R, and the role of GRKs in D2R–β-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine the extent to which β-arrestin recruitment to the D2R is GRK-dependent. Genetic elimination of all GRK expression decreased, but did not eliminate, agonist-stimulated β-arrestin recruitment to the D2R or its subsequent internalization. However, these processes were rescued upon the re-introduction of various GRK isoforms in the cells with GRK2/3 also enhancing dopamine potency. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, decreased β-arrestin recruitment and receptor internalization, highlighting the importance of this GRK subfamily for D2R–β-arrestin interactions. These results were recapitulated using a phosphorylation-deficient D2R mutant, emphasizing that GRKs can enhance β-arrestin recruitment and activation independently of receptor phosphorylation.
- Open Access
- 30 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 12141-12162
Pharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.
- 30 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (17) , 12141-12162
Open AccessPharmacology and Therapeutic Potential of Benzothiazole Analogues for Cocaine Use Disorder
Pharmacological targeting of the dopamine D4 receptor (D4R)─expressed in brain regions that control cognition, attention, and decision-making─could be useful for several neuropsychiatric disorders including substance use disorders (SUDs). This study focused on the synthesis and evaluation of a novel series of benzothiazole analogues designed to target D4R. We identified several compounds with high D4R binding affinity (Ki ≤ 6.9 nM) and >91-fold selectivity over other D2-like receptors (D2R, D3R) with diverse partial agonist and antagonist profiles. Novel analogue 16f is a potent low-efficacy D4R partial agonist, metabolically stable in rat and human liver microsomes, and has excellent brain penetration in rats (AUCbrain/plasma > 3). 16f (5-30 mg/kg, i.p.) dose-dependently decreased iv cocaine self-administration in rats, consistent with previous results produced by D4R-selective antagonists. Off-target antagonism of 5-HT2A or 5-HT2B may also contribute to these effects. Results with 16f support further efforts to target D4R in SUD treatment.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 281
Structure–Activity Relationships of a Brain-Penetrant D3 Dopamine Receptor Negative Allosteric Modulator and Investigation of its Binding Site
ID 15773 Poster Board 281 Dopamine receptors (DARs) are G-protein coupled receptors (GPCRs) that regulate diverse physiological functions including cognition, mood, movement, and reward-related behaviors, and are involved in the treatment or etiology of many neuropsychiatric disorders including schizophrenia and substance use disorder (SUD). DARs are classified as either D1-like (D1R and D5R) or D2-like (D2R, D3R, and D4R) based on structural homology and pharmacological profiles. Antagonists of D2-like DARs are currently used in the therapies for many neuropsychiatric disorders, but D3R-selective antagonists may be better therapeutics for schizophrenia or SUD as they could attenuate psychotic or drug craving symptoms without the motor side effects frequently produced by D2R-preferring antagonists due to limited distribution of the D3R in the brain. However, discovery of D3R-selective compounds is challenging due to high sequence homology of the D2R and D3R within their orthosteric binding sites, leading to the potential for off-target side effects produced by currently available compounds due to simultaneous antagonism of both subtypes or other closely related receptors. Our lab has endeavored to overcome the selectivity challenges posed by orthosteric antagonists by utilizing a D3R-mediated β-arrestin recruitment assay to screen the NIH Molecular Libraries Program 400,000+ small molecule library for compounds that inhibit the D3R via binding to less conserved allosteric sites. The most potent hit compound, MLS6357, was selective for the D3R versus the D2R and D4R in several functional outputs including β-arrestin recruitment and G-protein activation. Radioligand binding and functional assays using closely related GPCRs revealed that MLS6357 has very limited cross-reactivity with other GPCRs. Additionally, Schild-type functional assays showed that MLS6357 acts as a purely non-competitive negative allosteric modulator (NAM) of the D3R. We synthesized and characterized > 70 analogs of MLS6357 using iterative medicinal chemistry approaches which produced analogs that are 100-fold and 60-fold more potent than the parent compound in D3R-mediated β-arrestin recruitment and G-protein activation assays, respectively, and revealed structure–activity relationships for further optimization of the scaffold. Moreover, some analogs appear to display functional selectivity for inhibition of G-protein activation versus inhibition of β-arrestin recruitment, and vice versa, and some also display inverse agonist activity in G-protein signaling assays. Using in vivo pharmacokinetic experiments in mice via i.p. administration, one of the lead analogs was found to be brain penetrant and achieved sufficient concentrations to occupy the D3R in vivo. To identify the allosteric binding site for the MLS6357 scaffold on the D3R, we utilized various D3R/D2R chimeras, receptor mutants, and molecular modeling techniques to reveal and characterize receptor regions necessary for compound efficacy. Further refinement of the binding pocket for MLS6357 will inform future medicinal chemistry efforts. Ultimately, this novel scaffold may be of benefit as a pharmacological probe or therapeutic lead for D3R-related pathophysiology.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 281
Open AccessStructure–Activity Relationships of a Brain-Penetrant D3 Dopamine Receptor Negative Allosteric Modulator and Investigation of its Binding Site
ID 15773 Poster Board 281 Dopamine receptors (DARs) are G-protein coupled receptors (GPCRs) that regulate diverse physiological functions including cognition, mood, movement, and reward-related behaviors, and are involved in the treatment or etiology of many neuropsychiatric disorders including schizophrenia and substance use disorder (SUD). DARs are classified as either D1-like (D1R and D5R) or D2-like (D2R, D3R, and D4R) based on structural homology and pharmacological profiles. Antagonists of D2-like DARs are currently used in the therapies for many neuropsychiatric disorders, but D3R-selective antagonists may be better therapeutics for schizophrenia or SUD as they could attenuate psychotic or drug craving symptoms without the motor side effects frequently produced by D2R-preferring antagonists due to limited distribution of the D3R in the brain. However, discovery of D3R-selective compounds is challenging due to high sequence homology of the D2R and D3R within their orthosteric binding sites, leading to the potential for off-target side effects produced by currently available compounds due to simultaneous antagonism of both subtypes or other closely related receptors. Our lab has endeavored to overcome the selectivity challenges posed by orthosteric antagonists by utilizing a D3R-mediated β-arrestin recruitment assay to screen the NIH Molecular Libraries Program 400,000+ small molecule library for compounds that inhibit the D3R via binding to less conserved allosteric sites. The most potent hit compound, MLS6357, was selective for the D3R versus the D2R and D4R in several functional outputs including β-arrestin recruitment and G-protein activation. Radioligand binding and functional assays using closely related GPCRs revealed that MLS6357 has very limited cross-reactivity with other GPCRs. Additionally, Schild-type functional assays showed that MLS6357 acts as a purely non-competitive negative allosteric modulator (NAM) of the D3R. We synthesized and characterized > 70 analogs of MLS6357 using iterative medicinal chemistry approaches which produced analogs that are 100-fold and 60-fold more potent than the parent compound in D3R-mediated β-arrestin recruitment and G-protein activation assays, respectively, and revealed structure–activity relationships for further optimization of the scaffold. Moreover, some analogs appear to display functional selectivity for inhibition of G-protein activation versus inhibition of β-arrestin recruitment, and vice versa, and some also display inverse agonist activity in G-protein signaling assays. Using in vivo pharmacokinetic experiments in mice via i.p. administration, one of the lead analogs was found to be brain penetrant and achieved sufficient concentrations to occupy the D3R in vivo. To identify the allosteric binding site for the MLS6357 scaffold on the D3R, we utilized various D3R/D2R chimeras, receptor mutants, and molecular modeling techniques to reveal and characterize receptor regions necessary for compound efficacy. Further refinement of the binding pocket for MLS6357 will inform future medicinal chemistry efforts. Ultimately, this novel scaffold may be of benefit as a pharmacological probe or therapeutic lead for D3R-related pathophysiology.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 148
GRK2 Enhances ß-arrestin Recruitment to the D2 Dopamine Receptor Through a Mechanism that is Independent From Receptor Phosphorylation or G Protein Activation
ID 19401 Poster Board 148 The D2 dopamine receptor (D2R) interacts with and signals through both G proteins and ss-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. ß-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at two interfaces: the receptor core and the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, this post-translational modification is indispensable for ß-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for ß-arrestin recruitment to the D2R, and the role of GRKs in D2R-ß-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine if ß-arrestin recruitment to the D2R was GRK-dependent. Genetic elimination of all GRK expression significantly decreased, but did not totally eliminate, both ß-arrestin recruitment to the D2R and receptor internalization. However, these processes were rescued upon re-introduction of various GRK isoforms in the cells via transient transfection. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, dose-dependently decreased ß-arrestin recruitment and receptor internalization, highlighting the importance of these kinases for D2R-ß-arrestin interactions. Interestingly, these results were recapitulated using a phosphorylation-deficient (PO4-null) D2R mutant, emphasizing that GRKs enhance D2R-ß-arrestin interactions independently from receptor phosphorylation. As GRK2/3 are well known to interact with the ß-γ subunits of G proteins following heterotrimer dissociation, we investigated the role of G proteins in GRK functionality at the D2R. Inhibition of G protein signaling with pertussis toxin modestly decreased ß-arrestin recruitment to the D2R in cells expressing endogenous amounts of GRKs but had no effect when GRK2 was overexpressed. We also used a mutant GRK2 that is unable to bind to ß-γ G protein subunits (GRK2-R587Q) and found that ß-γ interactions were not necessary for this function of GRK2. Next, we investigated if the catalytic activity of GRK2 is required to enhance D2R-ß-arrestin interactions. Overexpression of a catalytically inactive GRK2 mutant (GRK2-K220R) did not enhance ß-arrestin recruitment or receptor internalization in cells expressing endogenous amounts of GRKs. However, when transfected into GRK-KO cells, GRK2-K220R rescued ß-arrestin recruitment and D2R internalization, albeit to a slightly lesser extent than WT GRK2. However, we found that GRK2-K220R is recruited to the D2R less efficiently than WT GRK2 in both parental and GRK-KO cells. Therefore, its lack of effect when overexpressed in parental cells could be due to competition from endogenous GRKs. Further, the reduced ability of GRK2-K220R to interact with the D2R could explain its reduced ability to drive ß-arrestin recruitment compared to WT GRK2. In summary, we demonstrate that GRKs, especially GRK2/3, are necessary for maximal agonist-stimulated D2R-ß-arrestin interactions, however, their kinase activities are not required. We hypothesize that GRK2 might act through a novel non-catalytic, scaffolding mechanism to enhance ß-arrestin recruitment to the D2R, highlighting the diversity with which GPCRs can interact with signal transduction proteins.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 148
Open AccessGRK2 Enhances ß-arrestin Recruitment to the D2 Dopamine Receptor Through a Mechanism that is Independent From Receptor Phosphorylation or G Protein Activation
ID 19401 Poster Board 148 The D2 dopamine receptor (D2R) interacts with and signals through both G proteins and ss-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. ß-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at two interfaces: the receptor core and the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, this post-translational modification is indispensable for ß-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for ß-arrestin recruitment to the D2R, and the role of GRKs in D2R-ß-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine if ß-arrestin recruitment to the D2R was GRK-dependent. Genetic elimination of all GRK expression significantly decreased, but did not totally eliminate, both ß-arrestin recruitment to the D2R and receptor internalization. However, these processes were rescued upon re-introduction of various GRK isoforms in the cells via transient transfection. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, dose-dependently decreased ß-arrestin recruitment and receptor internalization, highlighting the importance of these kinases for D2R-ß-arrestin interactions. Interestingly, these results were recapitulated using a phosphorylation-deficient (PO4-null) D2R mutant, emphasizing that GRKs enhance D2R-ß-arrestin interactions independently from receptor phosphorylation. As GRK2/3 are well known to interact with the ß-γ subunits of G proteins following heterotrimer dissociation, we investigated the role of G proteins in GRK functionality at the D2R. Inhibition of G protein signaling with pertussis toxin modestly decreased ß-arrestin recruitment to the D2R in cells expressing endogenous amounts of GRKs but had no effect when GRK2 was overexpressed. We also used a mutant GRK2 that is unable to bind to ß-γ G protein subunits (GRK2-R587Q) and found that ß-γ interactions were not necessary for this function of GRK2. Next, we investigated if the catalytic activity of GRK2 is required to enhance D2R-ß-arrestin interactions. Overexpression of a catalytically inactive GRK2 mutant (GRK2-K220R) did not enhance ß-arrestin recruitment or receptor internalization in cells expressing endogenous amounts of GRKs. However, when transfected into GRK-KO cells, GRK2-K220R rescued ß-arrestin recruitment and D2R internalization, albeit to a slightly lesser extent than WT GRK2. However, we found that GRK2-K220R is recruited to the D2R less efficiently than WT GRK2 in both parental and GRK-KO cells. Therefore, its lack of effect when overexpressed in parental cells could be due to competition from endogenous GRKs. Further, the reduced ability of GRK2-K220R to interact with the D2R could explain its reduced ability to drive ß-arrestin recruitment compared to WT GRK2. In summary, we demonstrate that GRKs, especially GRK2/3, are necessary for maximal agonist-stimulated D2R-ß-arrestin interactions, however, their kinase activities are not required. We hypothesize that GRK2 might act through a novel non-catalytic, scaffolding mechanism to enhance ß-arrestin recruitment to the D2R, highlighting the diversity with which GPCRs can interact with signal transduction proteins.
- 30 December 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (1) , 151-170
Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity - ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptional in vivo selectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit ″atypical″ antipsychotic activity in humans with significantly fewer side effects than observed with the currently FDA-approved D2R antagonists.
- 30 December 2022
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 6 (1) , 151-170
Identification and Characterization of ML321: A Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity - ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptional in vivo selectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit ″atypical″ antipsychotic activity in humans with significantly fewer side effects than observed with the currently FDA-approved D2R antagonists.
- Open Access
Identification and Characterization of ML321: a Novel and Highly Selective D 2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity – ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R, and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptional in vivo selectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit “atypical” antipsychotic activity in humans with significantly fewer side effects than observed with currently FDA-approved D2R antagonists.
Open AccessIdentification and Characterization of ML321: a Novel and Highly Selective D 2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity
We have developed and characterized a novel D2R antagonist with exceptional GPCR selectivity – ML321. In functional profiling screens of 168 different GPCRs, ML321 showed little activity beyond potent inhibition of the D2R, and to a lesser extent the D3R, demonstrating excellent receptor selectivity. The D2R selectivity of ML321 may be related to the fact that, unlike other monoaminergic ligands, ML321 lacks a positively charged amine group and adopts a unique binding pose within the orthosteric binding site of the D2R. PET imaging studies in non-human primates demonstrated that ML321 penetrates the CNS and occupies the D2R in a dose-dependent manner. Behavioral paradigms in rats demonstrate that ML321 can selectively antagonize a D2R-mediated response (hypothermia) while not affecting a D3R-mediated response (yawning) using the same dose of drug, thus indicating exceptional in vivo selectivity. We also investigated the effects of ML321 in animal models that are predictive of antipsychotic efficacy in humans. We found that ML321 attenuates both amphetamine- and phencyclidine-induced locomotor activity and restored pre-pulse inhibition (PPI) of acoustic startle in a dose-dependent manner. Surprisingly, using doses that were maximally effective in both the locomotor and PPI studies, ML321 was relatively ineffective in promoting catalepsy. Kinetic studies revealed that ML321 exhibits slow-on and fast-off receptor binding rates, similar to those observed with atypical antipsychotics with reduced extrapyramidal side effects. Taken together, these observations suggest that ML321, or a derivative thereof, may exhibit “atypical” antipsychotic activity in humans with significantly fewer side effects than observed with currently FDA-approved D2R antagonists.
- Open Access
- 22 May 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-2
Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential
- 22 May 2021
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 6 (1) , 1-2
Open AccessNovel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Optimization of ML321: a D 2 dopamine receptor‐selective antagonist for the treatment of neuropsychiatric disorders
FDA‐approved antipsychotics treat the positive symptoms of schizophrenia by targeting and blocking the D 2 dopamine receptor (D2R). However, current treatment is hindered by numerous side‐effects due to off‐target activities at other GPCRs and unfavorable binding kinetics at the D2R. We have identified a lead antipsychotic candidate, ML321, using high throughput screening to identify selective D2R antagonists. ML321 demonstrates global selectivity for inhibiting the D2R, and to a lesser extent the D3R, with little activity at other GPCR targets. Additionally, ML321 has optimal binding kinetics at the D2R with slow association and fast dissociation rates to/from the receptor – properties that may limit commonly observed extrapyramidal side effects (EPS). In fact, ML321 does not produce catalepsy in rodents, a behavior that models the EPS observed with many antipsychotics. Moreover, behavioral assays demonstrate that ML321 is effective in animal models that are predictive of antipsychotic efficacy in humans (e.g., attenuation of both amphetamine and PCP‐induced locomotor activity and pre‐pulse inhibition). Importantly, no other D2R antagonist exhibits this pharmacological and behavioral profile supporting its development into an advanced drug lead. No concerns were noted during safety/toxicity studies including hERG channel activation, cytotoxicity, the AMES test, and a CYP inhibition study. While a promising therapeutic, it has a short metabolic half‐life, impeding its clinical development. To this end, we have determined the metabolic ID of ML321 and designed, synthesized, and tested a series of ML321 analogs with modifications of the site of primary metabolism (the alkyl‐thiophene moiety) in an effort to metabolically stabilize the scaffold while maintaining its favorable pharmacological properties. Over 55 ML321 analogs have been synthesized and pharmacologically characterized using radioligand binding and functional b‐arrestin recruitment assays. Simultaneously, in vitro ADME properties including metabolic stability, permeability, and solubility have been determined for each analog. These studies have led to the optimization of the compound into a collection of lead clinical candidates that show similar pharmacology to ML321 but with marked increases in metabolic stability and ADME properties. These findings refine our understanding of ML321 structure‐activity relationships, particularly around the alkyl‐thiophene moiety. Based on this information, additionally optimized analogs have been designed and synthesized supporting the notion that ML321 can be developed into an advanced drug lead with the potential to be a superior therapeutic for the treatment of schizophrenia and other psychotic disorders.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessOptimization of ML321: a D 2 dopamine receptor‐selective antagonist for the treatment of neuropsychiatric disorders
FDA‐approved antipsychotics treat the positive symptoms of schizophrenia by targeting and blocking the D 2 dopamine receptor (D2R). However, current treatment is hindered by numerous side‐effects due to off‐target activities at other GPCRs and unfavorable binding kinetics at the D2R. We have identified a lead antipsychotic candidate, ML321, using high throughput screening to identify selective D2R antagonists. ML321 demonstrates global selectivity for inhibiting the D2R, and to a lesser extent the D3R, with little activity at other GPCR targets. Additionally, ML321 has optimal binding kinetics at the D2R with slow association and fast dissociation rates to/from the receptor – properties that may limit commonly observed extrapyramidal side effects (EPS). In fact, ML321 does not produce catalepsy in rodents, a behavior that models the EPS observed with many antipsychotics. Moreover, behavioral assays demonstrate that ML321 is effective in animal models that are predictive of antipsychotic efficacy in humans (e.g., attenuation of both amphetamine and PCP‐induced locomotor activity and pre‐pulse inhibition). Importantly, no other D2R antagonist exhibits this pharmacological and behavioral profile supporting its development into an advanced drug lead. No concerns were noted during safety/toxicity studies including hERG channel activation, cytotoxicity, the AMES test, and a CYP inhibition study. While a promising therapeutic, it has a short metabolic half‐life, impeding its clinical development. To this end, we have determined the metabolic ID of ML321 and designed, synthesized, and tested a series of ML321 analogs with modifications of the site of primary metabolism (the alkyl‐thiophene moiety) in an effort to metabolically stabilize the scaffold while maintaining its favorable pharmacological properties. Over 55 ML321 analogs have been synthesized and pharmacologically characterized using radioligand binding and functional b‐arrestin recruitment assays. Simultaneously, in vitro ADME properties including metabolic stability, permeability, and solubility have been determined for each analog. These studies have led to the optimization of the compound into a collection of lead clinical candidates that show similar pharmacology to ML321 but with marked increases in metabolic stability and ADME properties. These findings refine our understanding of ML321 structure‐activity relationships, particularly around the alkyl‐thiophene moiety. Based on this information, additionally optimized analogs have been designed and synthesized supporting the notion that ML321 can be developed into an advanced drug lead with the potential to be a superior therapeutic for the treatment of schizophrenia and other psychotic disorders.